Compare Novartis AG (NVS) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Uranium Energy Corp — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Uranium Energy Corp trades at $9.37 (market cap $4.69B). The key difference: Novartis AG is far larger — about 58.4× Uranium Energy Corp's market cap, and Novartis AG pays a 3.31% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Uranium Energy Corp for 37 Days on average.
| NVS | UEC | |
|---|---|---|
Market Cap | $274.00B | $4.69B |
Volume | 1,852,137 | 8,957,476 |
Sector | Health | Energy |
52-Week High | $168.62 | $20.14 |
52-Week Low | $121.80 | $9.04 |
Typical Hold Time | 82 Days | 37 Days |
Enterprise Value | $315.32B | $4.20B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Uranium Energy (UEC) trades at $9.47, down 6.33% today, amid bearish technical signals despite strong analyst support. The company reported fiscal 2026 revenue of $37M with a net loss of $137M, reflecting operational expansion but negative profitability. Recent news highlights UEC's transition to a multi-mine producer with improved production scale and a $93.13 realized uranium price, though earnings quality concerns persist due to inventory-driven revenue.
UEC presents a high-risk, high-reward opportunity with Wall Street optimism (87.5% buy ratings, $16.06 consensus target) contrasting weak fundamentals. Key risks include sustained losses, unproven production sustainability, and uranium price volatility. The stock's upside depends on successful execution of U.S. uranium production ramp-up amid growing nuclear demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
